BIOCAD’s rituximab biosimilar to receive MA soon in India

04.07.2017

BIOCAD’s rituximab biosimilar to receive MA soon in India

 On 20th of June 2017, the Central Drugs Standard Control Organization (CDSCO) has recommended Acellbia, the first rituximab biosimilar made in Russia, for approval in India.  In August 2017, BIOCAD will receive permanent market authorization in India, which represents a strategic milestone for BIOCAD’s international expansion.

More Category: Media release
BIOCAD registered the first rituximab biosimilar in Bolivia and Honduras

06.06.2017

BIOCAD registered the first rituximab biosimilar in Bolivia and Honduras

In 2017, BIOCAD obtained a marketing authorization for its rituximab biosimilar in Bolivia and Honduras under the trade name USMAL. First shipments will start in the beginning of the third quarter of 2017. BIOCAD will be able to supply as much rituximab as needed for Bolivian and Honduran patients. Considering competitive price of the Russian biosimilar, estimated drug availability will double.

More Category: News
BIOCAD keeps on supplying its medicine for blood cancer treatment in Vietnam

30.03.2017

BIOCAD keeps on supplying its medicine for blood cancer treatment in Vietnam

In March BIOCAD biotechnology company was granted access to supply highly demanded medicine - rituximab biosimilar to Vietnam for a second time. It means that BIOCAD partners will continue to supply local hospitals with the Russian product and patients will get access to affordable and effective treatment in Vietnam.     

More Category: Media release
Innovative Russian drug product mobilizes human immune system to fight cancer

06.02.2017

Innovative Russian drug product mobilizes human immune system to fight cancer

Revolutionary Russian anti-cancer anti-PD1 medicine candidate has successfully ended pre-clinical animal trials, i.e. on primates. So far the product has demonstrated higher efficacy than the only two approved medicines acting  against the same therapeutic target – pembrolizumab from Merck and nivolumab from BMS. 

BIOCAD is now preparing for the first international multi-center clinical trials. Patients in Russia will be among the first to get access to the new generation therapy.  The medicine is expected to be available to patients as early as in 2018 or 2019.

More Category: Media release
Advanced rheumatoid arthritis medicine developed in Russia

11.07.2016

Advanced rheumatoid arthritis medicine developed in Russia

Biotechnological company BIOCAD has developed innovative medicine for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other autoimmune diseases.

More Category: Media release